Vasomotor symptoms (VMS), including hot flashes and night sweats, can significantly impact quality of life, causing distress, prolonged discomfort, and daily disruption. While many treatments are available, limited awareness of nonhormonal options can prevent patients from accessing effective care.
This program will review the clinical evidence for NK3 antagonists as a nonhormonal treatment option for VMS. By the end of the session, clinicians will be better prepared to implement new treatments into practice, when appropriate, using effective clinical decision-making.
This program has received an unrestricted educational grant or in-kind support from Astellas Pharma Canada Inc.
